Align Technology, Inc. (NASDAQ:ALGN) Rating Reiterated by Morgan Stanley

Morgan Stanley reiterated their overweight rating on shares of Align Technology, Inc. (NASDAQ:ALGN) in a report issued on Friday, October 6th. The brokerage currently has a $220.00 target price on the medical equipment provider’s stock, up from their previous target price of $195.00.

A number of other research analysts have also weighed in on ALGN. Northcoast Research reaffirmed a buy rating and issued a $186.00 price target (up from $164.00) on shares of Align Technology in a research note on Wednesday, June 21st. Stifel Nicolaus reissued a buy rating and issued a $200.00 target price (up from $145.00) on shares of Align Technology in a research note on Friday, June 23rd. Leerink Swann raised their target price on shares of Align Technology from $149.00 to $194.00 and gave the stock an outperform rating in a research note on Monday, June 26th. Credit Suisse Group reissued an outperform rating and issued a $170.00 target price (up from $140.00) on shares of Align Technology in a research note on Thursday, July 13th. Finally, Bank of America Corporation raised shares of Align Technology from a neutral rating to a buy rating and raised their target price for the stock from $175.00 to $193.00 in a research note on Friday, July 28th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Align Technology presently has a consensus rating of Buy and an average price target of $198.50.

Align Technology (NASDAQ ALGN) opened at 194.23 on Friday. The stock’s 50 day moving average price is $185.70 and its 200-day moving average price is $156.83. The stock has a market cap of $15.57 billion, a PE ratio of 66.52 and a beta of 1.54. Align Technology has a 12 month low of $83.27 and a 12 month high of $196.00.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.12. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The company had revenue of $356.50 million for the quarter, compared to the consensus estimate of $343.43 million. During the same period last year, the firm earned $0.62 EPS. The firm’s revenue for the quarter was up 32.3% compared to the same quarter last year. Analysts anticipate that Align Technology will post $3.41 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/align-technologys-algn-overweight-rating-reiterated-at-morgan-stanley/1703000.html.

A number of institutional investors have recently bought and sold shares of ALGN. Schroder Investment Management Group acquired a new position in shares of Align Technology in the second quarter worth $104,000. CENTRAL TRUST Co grew its stake in shares of Align Technology by 128.5% in the second quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 392 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Align Technology by 6.9% in the first quarter. Van ECK Associates Corp now owns 1,057 shares of the medical equipment provider’s stock worth $121,000 after acquiring an additional 68 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Align Technology by 13.0% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock worth $137,000 after acquiring an additional 105 shares in the last quarter. Finally, BlueMountain Capital Management LLC acquired a new position in shares of Align Technology in the second quarter worth $148,000. Hedge funds and other institutional investors own 81.53% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley


Leave a Reply

 
© 2006-2017 BBNS.